DHA for PREGnant women: is the current recommendation appropriate for women with very low intake and status?

DHA supplementation to improve maternal, foetal and infant outcomes: is the current recommendation appropriate for women with very low intake and status?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN03848493

Enrollment

180

Registered

2014-08-20

Start date

2014-09-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Nutritional, Metabolic, Endocrine

Interventions

Participants will be asked to take one of three supplements: 1. 575 mg omega 3 FA (contains 322.5 mg DHA & 47.2 mg EPA) 2. 1,725 mg omega 3 FA (contains 967.7 mg DHA & 141.5 mg EPA) 3. Placebo (contai

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Healthy women with singleton pregnancy

Exclusion criteria

Exclusion criteria: 1. Pre-existing chronic medical conditions such as diabetes, high blood pressure, congenital heart disease, kidney disease, very preterm delivery 2. Sickle cell disease or hemoglobinopathies 3. History of pre-eclampsia, stillbirth or foetal death, major foetal anomaly 4. Smoking or other illegal-substance abuse

Design outcomes

Primary

Measure	Time frame
DHA level in maternal and cord blood at delivery	—

Secondary

Measure	Time frame
1. DHA level in breast milk at postnatal week 6 2. Anthropometric measurement of babies at birth and postnatal week 6	—

Countries

Sudan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026